| 16.99 -0.23 (-1.34%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.72 | 1-year : | 24.2 |
| Resists | First : | 17.73 | Second : | 20.72 |
| Pivot price | 15.6  |
|||
| Supports | First : | 13.67 |
Second : | 11.15 |
| MAs | MA(5) : | 16.62 |
MA(20) : | 15.07 |
| MA(100) : | 18.71 |
MA(250) : | 24.95 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 87.1 |
D(3) : | 87.6 |
| RSI | RSI(14): 68.1 |
|||
| 52-week | High : | 39.79 | Low : | 10.8 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ INBX ] has closed below upper band by 17.4%. Bollinger Bands are 37% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.49 - 17.59 | 17.59 - 17.67 |
| Low: | 16.76 - 16.88 | 16.88 - 16.98 |
| Close: | 16.81 - 16.99 | 16.99 - 17.14 |
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Wed, 18 Sep 2024
Inhibrx, Inc. (NASDAQ:INBX) Short Interest Update - MarketBeat
Fri, 13 Sep 2024
Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX) By GuruFocus - Investing.com Canada
Tue, 10 Sep 2024
Inhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe Purchases 9,500 Shares - MarketBeat
Tue, 23 Jul 2024
Inhibrx stock rated 'Market Perform' by JMP after Sanofi acquisition - Investing.com
Fri, 07 Jun 2024
Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi (NASDAQ:INBX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1.448e+007 (%) |
| Held by Institutions | 7.73e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 118.83 |
| Profit Margin | 101 % |
| Operating Margin | 974.2 % |
| Return on Assets (ttm) | -160 % |
| Return on Equity (ttm) | 898 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 172.36 |
| Sales Per Share | -165.04 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.0093e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0.14 |
| Price to Sales | -0.11 |
| Price to Cash Flow | 0 |
| Dividend | 700660 |
| Forward Dividend | 710370 |
| Dividend Yield | 4123960% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|